The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions.
Maria Mastrogiannaki, Pavle Matak, Carole Peyssonnaux

To cite this version:

HAL Id: inserm-01068507
http://www.hal.inserm.fr/inserm-01068507
Submitted on 25 Sep 2014

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions

Maria Mastrogiannaki,1-3 Pavle Matak,1-3 and Carole Peyssonnaux1-3

1Institut National de la Santé et de la Recherche Médicale (INSERM), U1016, Institut Cochin, Paris, France; 2Centre National de la Recherche Scientifique, UMR8104, Paris, France; and 3Université Paris Descartes, Sorbonne Paris Cité, Paris, France

Although earlier, seminal studies demonstrated that the gut per se has the intrinsic ability to regulate the rates of iron absorption, the spotlight in the past decade has been placed on the systemic regulation of iron homeostasis by the hepatic hormone hepcidin and the molecular mechanisms that regulate its expression. Recently, however, attention has returned to the gut based on the finding that hypoxia inducible factor-2 (HIF-2α) regulates the expression of key genes that contribute to iron absorption. Here we review the current understanding of the molecular mechanisms that regulate iron homeostasis in the gut by focusing on the role of HIF-2 under physiological steady-state conditions and in the pathogenesis of iron-related diseases. We also discuss implications for adapting HIF-2–based therapeutic strategies in iron-related pathological conditions. (Blood. 2013;122(6):885-892)

Introduction

Iron (Fe) is an essential nutrient required in many cellular biosynthetic and metabolic processes such as heme and sulfur-iron cluster biosynthesis, oxygen transport, mitochondrial respiration, and DNA replication. The body of a healthy human male contains ~4 g of total iron, which is in a dynamic equilibrium between different tissues: 1 g is predominantly stored in hepatocytes, whereas 65% to 80% of total iron traffics in a closed circuit in which erythropoiesis of senescent red blood cells by reticuloendothelial macrophages in the spleen enables iron to be returned to the bone marrow for incorporation into new erythrocytes. Approximately 1 mg of dietary iron is absorbed daily at the proximal duodenum, a process that is essential in order to replace daily losses due to limited blood losses, desquamation, and so forth. Excess iron accumulation and the resulting production of reactive oxygen species through the Fenton/Haber Weiss reaction are involved in the pathogenesis of iron-overload–related diseases including hereditary hemochromatosis (HH) and β-thalassemia.

Iron absorption is increased during iron deficiency and decreased upon iron loading. This inverse relationship depends on a network of signals, which reflect systemic body iron requirements and the interaction of these signals with the enterocyte iron sensing and transport machinery. Iron homeostasis is regulated systemically by the hormone hepcidin, a 25-amino-acid peptide produced mainly by the hepatocytes. Hepcidin expression is increased by iron loading and inflammatory signals and is attenuated by iron deficiency, anemia, increased erythropoietic activity, and hypoxia. Hepcidin inhibits iron absorption and iron recycling by binding to the only known iron exporter, ferroportin (FPN). Recent advances in the understanding of the regulation of hepcidin expression and the mechanism of hepcidin action have been detailed elsewhere.

Here, we review current knowledge regarding the roles of hypoxia inducible factor-2 (HIF-2) and iron regulatory proteins 1 (IRP1) and 2 (IRP2) in the molecular circuitry that regulates iron absorption by enterocytes. We also discuss recent findings demonstrating the importance of IRP1-dependent regulation of HIF-2 in the regulation of iron homeostasis and implications in the context of iron-related pathophysiological conditions.

Key molecules regulating iron homeostasis in the gut

Dietary iron is broadly classified into 2 categories based on chemical form. The majority of iron is nonheme iron, which is present in most foods, including cereal, vegetables, and meat. It is found in ferritin (Ft) and other proteins, as well as several nonprotein-bound forms. Iron that is present in heme is mainly found in meat.

The solubility of ferric salts or nonheme iron is highly dependent on a variety of intraluminal parameters, including pH. In the presence of reductive factors or reductases, ferric iron (Fe3⁺) is reduced to the ferrous (Fe2⁺) form at the brush border membrane. Duodenal cytochrome b561 (DCYTB), a diheme-containing and ascorbate-dependent ferric enzyme, has been proposed to mediate this reductive event in the duodenum. While Dcytb knockout mice display no overt defects in iron homeostasis when subjected to iron-rich or iron-deficient diets, they have less nonheme iron in the spleen and significantly lower reticulocyte mean corpuscular hemoglobin when compared with control mice. Ferric reductases belonging to the Steap family also have been proposed to act at the brush border membrane.

Fe2⁺ can be transported via divalent metal-ion transporter 1 (DMT1/NRAMP2). DMT1 is a proton-coupled metal transporter of a broad range of divalent ions, although Fe2⁺ is its principal physiological substrate. The importance of duodenal DMT1 in Fe2⁺ transport is underscored by the anemic phenotype of Dmt1 intestinal knockout mutants. Mutations of DMT1 in humans result in hypochromic microcytic anemia that may or may not be accompanied by massive hepatic iron overload.

Iron absorbed by mature enterocytes is either stored in Ft or exported across the basolateral enterocyte membrane into the plasma by FPN. Ft is a globular protein composed of both H (FtH) and...
Fe predominantly as a folate transporter.21 Therefore, the mechanism of but in vivo studies indicate that heme carrier protein 1 functions carrier protein 1 has been proposed as an intestinal heme transporter, HEPH activity (eg, due to copper de

HEPH.18 HEPH catalyzes the oxidation of Fe

carrier protein level.7,11,28,29 Hepatic hepcidin expression is inversely correlated with DMT1, DCYTB, and FPN at the messenger RNA (mRNA) and protein level. These findings indicate that local enterocyte iron levels can

determine of this NDFIPs-WWP2 pathway in the hepcidin-mediated degradation of DMT1 remains to be demonstrated.

Local regulation of iron absorption in enterocytes

Although it is widely recognized that low liver hepcidin expression contributes to the upregulated expression of iron transporters during iron deficiency, in vitro evidence has suggested that the upregulated expression of iron transporters that occurs following exposure to desferroxamine, an iron chelator, occurs in a cell-autonomous manner.28 Cell-autonomous regulation of duodenal iron absorption in response to hypoxia has also been well documented. Early experimental evidence supported the notion that acute hypoxia affects apical iron uptake independently of systemic cues such as erythropoietic drive or hepcidin levels: increased apical iron uptake was observed in rats as early as 6 to 8 hours after initiation of hypoxia.37,38 This early induction precedes changes in circulating iron levels or erythropoiesis37,38 or a decrease in hepcidin occurring only after at least 24 hours of hypoxia in mice39 and in humans.40,41 In addition, this hypoxic response increased iron absorption but was independent of dietary or mucosal iron status.42

Although the effect of increased erythropoiesis on iron absorption has generally been attributed to the strong downregulation of hepcidin expression, a direct effect of erythropoietin (EPO) on duodenal enterocytes has been recently proposed. Srai et al43 suggested that EPO acts directly on duodenal enterocytes through its receptor EPO-R to upregulate expression of iron transporters, based on findings in a nephrectomized rat model of chronic renal failure. Whether this mechanism is relevant in human pathological conditions characterized by ineffective erythropoiesis (such as β-thalassemia), or in murine experimental models of hypoxia or anemia characterized by high erythropoietic demand and iron absorption rates, remains to be established.

While iron deficiency and hypoxia promote iron absorption, oral administration of large doses of iron attenuates the subsequent absorption of smaller doses of iron administered hours later. This effect has been attributed to decreases in transcript and protein levels of both DCYT B and DMT1, which occur as early as 6 hours post iron administration, but not to changes in the expression of FPN or HEPH.44 These findings indicate that local enterocyte iron levels can directly regulate the apical membrane phase of iron transport.

Transcriptional regulation by HIF-2

The transcriptional regulation of genes involved in apical iron uptake and mucosal iron transfer was largely unknown until the recent discovery of the involvement of HIF-2 transcription factor in this process. The HIF transcription factors are central mediators of cellular adaptation to hypoxia.45 HIF is a heterodimer, and its expression is
principally regulated by oxygen. The HIF heterodimer consists of 2 helix-loop-helix proteins: an α-regulatory subunit, which is the oxygen- and iron-responsive component, and the β-subunit, also known as the aryl hydrocarbon receptor nuclear translocator, which is constitutively expressed. Three regulatory HIF subunits have been cloned and named HIF-1α, HIF-2α, and HIF-3α. To date, HIF-1α has been the most extensively studied. In the presence of oxygen, the hydroxylation of HIF-α at conserved proline residues within the oxygen-dependent degradation domain is the rate-limiting step for subsequent HIF-α protein degradation and is catalyzed by prolyl-4-hydroxylase domain enzymes (PHDs). Three PHD isoforms exist in mammals and are encoded by different genes: PHD1 (also known as egg laying defective gene [EGL] 9 homolog [EGLN] 2 or HIF prolyl hydroxylase [HPH] 3), PHD2 (EGLN1 or HPH2), and PHD3 (EGLN3 or HPH1). PHDs are iron- and 2-oxoglutarate–dependent dioxygenases utilizing O2 as a substrate, 2-oxoglutarate as a cosubstrate, and iron (Fe2+) and ascorbate as cofactors. The 4-hydroxyprolines are subsequently recognized by the protein von Hippel–Lindau (pVHL) E3 ubiquitin ligase, which targets HIF-α for degradation by the 26S proteasome through polyubiquitination by the E3-ubiquitin-ligase complex containing elongin B and C, cullin-2, and rbx1. The HIF heterodimer then binds within the DNA regulatory promoter or enhancer regions of target genes at specific locations termed hypoxia response elements (HREs) and recruits transcriptional coactivators, p300/CREB-binding protein, to activate transcription. Several links between regulation of HIF stability and iron homeostasis have been identified, and more recently, HIF-2 has emerged as an important “local” regulator of intestinal iron absorption that directly trans-activates the expression of iron transporter genes in enterocytes (Figure 1). Indeed, mice lacking HIF-2α in the intestinal epithelium exhibited significant decreases in the duodenal levels of Dmt1, Dcytb and Fpn mRNAs, effects that were not compensated by HIF-1. This decrease in the expression of genes involved in both apical and basolateral iron transport was associated with a significant reduction in plasma and liver iron content, and a marked decrease in hepatic hepcidin expression, demonstrating a pivotal role of HIF-2 in steady-state regulation of iron absorption. Although HIF-2 intestinal knockout mice did not show striking differences in the morphology of intestinal villi when compared with control mice, a potential effect of HIF-2 on enterocyte survival, proliferation, or shedding has not been systematically investigated.
and remains to be addressed in future studies of the role of HIF-2 in intestinal function.

The differential target gene specificity of HIF-2α vs HIF-1α in the duodenum may be due to interaction of the HIF-α N-terminal sequence with additional transcription factors, as has previously been suggested. Orthologs of Sp6 transcription factors possibly act in cooperation with HIF-2 to increase iron absorption. Further, certain physiological features of the intestinal epithelium may explain the phenotype of HIF-2α intestinal knockout mice at the basal level. The gastrointestinal tract has a unique tissue oxygenation profile under steady-state conditions. While the epithelium is in a relatively hypoxic state, the subepithelial mucosa is highly vascularized, and meal ingestion is known to increase the mucosal blood flow. Reduced blood flow in the villus microvasculature during the fasting period could thus result in a relatively hypoxic state of the duodenal enterocytes, which would stabilize HIF-2α, therefore potentiating the expression of DMT1 and DCTYTB in order to increase apical iron uptake during digestion of a subsequent meal. Alternatively, other mechanisms could affect local HIF-2α levels in the duodenal enterocytes, such as intraluminal pH levels. In human subjects, intraluminal duodenal pH fluctuates from 4.0 during meals to below 2.0 during the fasting period. Iron absorption of inorganic iron is influenced by pH. Given the links between pH regulation and HIF signaling, it is possible that low intraluminal pH may potentiate HIF-2α stabilization. Additionally, upregulation of duodenal HIF-2α is likely to occur at the protein level through diminished PHD activity in the hypoxic microvilli. Importantly, mice developing severe anemia and tissue hypoxia in response to phenyladrazine treatment do not exhibit changes in duodenal HIF-2α mRNA levels. Increased duodenal HIF-2α protein stabilization has been shown to mediate the upregulation of Dmt1 and Dctytb mRNAs in mice fed an iron-deficient diet. A biphasic regulation of duodenal FPN has been reported during iron deficiency in mice, in which HIF-2 is essential in the acute regulation of iron export but dispensable in the chronic phase. As iron absorption rates are higher in younger animals, it is also conceivable that HIF-2 might be more important during periods of postnatal growth than in adults. HIF-2 protein levels are also stabilized in various other conditions of high iron demand, such as hypoxia or phlebotomy (Figure 1). Altogether, these findings reveal an important role for HIF-2 in the iron- and oxygen-dependent regulation of iron absorption.

Posttranscriptional regulation by the IRPs: a new IRP1/HIF-2 axis

Posttranscriptional regulation of iron homeostasis genes in response to intracellular iron levels is mediated by IRPs, IRP1 and IRP2, which bind to IREs found in the 5′ or 3′ untranslated regions (UTRs) of target mRNAs. IRP1 and IRP2 protein abundance and IRE-binding activity are regulated by different mechanisms. IRP1 does not show detectable IRE-binding activity in the majority of tissues under physiological conditions, but rather is expressed in the form of a cytosolic aconitase. By contrast, the protein abundance of IRP2 is regulated by F-box and leucine-rich repeat protein 5, an iron- and oxygen-binding hemerythrin domain adaptor protein that recruits the SKP1–CUL1–F-box E3 ubiquitin ligase complex to promote IRP2 proteasomal degradation under iron-replete conditions. High IRE-binding activity in response to low intracellular iron levels results in translational repression of mRNAs that contain an IRE in their 5′UTR (such as Fpn, Fth, and Fetl) or promotes mRNA stability if bound to mRNAs that contain an IRE in 3′UTR (as in the case of Dmtl). Dmtl is present in different isoforms, and those transcript isoforms that contain an IRE predominate in the proximal intestine. Although activation of IRPs by iron deficiency would normally be expected to repress translation of FPN, duodenal FPN levels are increased in iron-deficient animals. Importantly, Zhang et al showed that an alternative Fpn mRNA lacking the 5′ UTR IRE motif (Fpn-IRE) is preferentially expressed in the duodenum, which could explain how enterocytes circumvent repression of FPN expression by IRE/IRP machinery. Mice carrying a deletion for both IRP1 and IRP2 in the intestinal epithelium present with decreased DMT1 and transferrin receptor 1 and increased Fih and Ftl protein levels, and they manifest malabsorption and villus structure disorganization associated with perinatal lethality. However, Irp2−/− and Irp1−/− mice are both viable but present different overt phenotypes. More specifically, mice with Irp2 deletion in the intestinal epithelium present with iron retention in the duodenal enterocytes, suggesting that IRP2 plays a cell-autonomous role in the intestine and also that IRP1 and IRP2 are partly redundant in the intestine. Furthermore, tissue-specific irp1−/− and/or irp2−/− knockout mouse models have demonstrated that IRP2 is the major regulator of iron homeostasis in vivo, responding to dietary iron deficiency and hypoxia. A 5′UTR IRE in the Hgfα2 mRNA has been characterized in vitro and may serve as an additional point of HIF-2 regulation. Sanchez et al proposed that HIF-2 translation may be enhanced in the presence of adequate levels of iron. In rats, hepatic HIF-2α has been shown to be translationally repressed in response to dietary iron deficiency compatible with a role for the IRE/IRP system in this process.

Two recent studies have demonstrated that translational regulation of HIF-2α synthesis by IRP1 in the kidney is critical for controlling erythropoiesis. Ghosh et al showed that irp1−/− mice develop pulmonary hypertension and polycythemia, a phenotype that is exacerbated in response to an iron-deficient diet and is caused by excessive EPO production resulting from the absence of translational repression of Hif-2α mRNA in the kidney. Interestingly, the authors also showed that secretion of the known HIF target endothelin-1 is highly upregulated in pulmonary endothelial cells isolated from irp1−/− mice compared with controls. Anderson et al further demonstrated that HIF-2 transcriptional activity is increased in the duodenum of irp1−/− mice, as indicated by the increased mRNA expression of Dmt1+IRE, Dctytb, and Fpn mRNAs, as well as other HIF-2 target genes. Moreover, Galy et al recently reported that IRPs regulate apical iron uptake by controlling FPN and DMT1 through HIF-2. They further showed that IRP deficiency in the adult mouse intestinal epithelium promotes a Ft-mediated “mucosal block.” As IRP activity is increased in the duodenum in response to iron deficiency, it might be hypothesized that Hif-2α is translationally repressed by IRP1. However, increased HIF-2α protein levels have been reported in the duodenum of iron-deficient mice. A possible explanation might be that during iron deficiency, the effects of IRP1 on Hif-2α mRNA translation are counteracted by the dominant stabilization of HIF-2α at the protein level, due to the decreased activities of PHDs (Figure 2). Moreover, IRP1 has been shown to decrease in hypoxia. As the duodenum is hypoxic, even at basal level, the decrease in IRP1 would amplify the impact of PHD-mediated regulation of HIF-2α accumulation. By contrast, high intracellular iron would prevent the translational repression of Hif-2α by IRP1 but potentially increase the activity of PHDs (Figure 2). However, models of intestinal iron overload coupled with systemic anemia indicate that elevated iron levels do not have a pronounced effect on HIF-2 per se and that systemic anemia/hypoxia is the predominant regulator of HIF-2. It would be interesting to examine these hypotheses more
specifically in mice with inducible deletion of Irp1 or Irp2 in the intestinal epithelium. Further studies addressing these questions may provide evidence for nonredundant roles of IRPs in the duodenum and their importance in integrating systemic physiological signals in vivo.

HIF-2: implications for iron-related disorders

Inflammation

Iron absorption is diminished during inflammatory conditions. Eventually, a decrease in serum iron limits iron availability to erythropoiesis and contributes to the anemia of inflammation (also called anemia of chronic disease [ACD]). Hypoferremia is mainly due to iron sequestration in macrophages of the reticuloendothelial system.

Hepatic hepcidin expression is markedly induced during infection and inflammation by cytokines (including interleukin [IL] 1 and IL-6), and urinary hepcidin levels are elevated in patients with chronic inflammatory diseases. IL-6 signals through binding to the IL-6 receptor and activates hepcidin transcription by binding of phosphorylated Signal Transducer and Activator of Transcription (STAT) to conserved sequence elements in the hepcidin promoter. The resulting hepcidin elevation is believed to play a major role in the pathogenesis of ACD. These features are reproducible in transgenic mouse models characterized by intestinal inflammation. However, the role of HIF-2 during intestinal inflammation has not yet been addressed. Interestingly, nitric oxide (NO), an important mediator of inflammation, has been shown to stimulate the IRE-binding activity of IRP1 in macrophages. Although this mechanism has not been validated in enterocytes, it is possible that NO-mediated translational repression of HIF-2 could contribute to the ability of inflammation to decrease in iron absorption.

Polycythemia/ineffective erythropoiesis

Erythrocytosis is caused by an exacerbated proliferation of erythrocyte progenitors in the bone marrow leading to an absolute increase in circulating red cell mass. Individuals who are exposed to high-altitude hypoxia develop erythrocytosis and an accompanying increase in iron absorption when compared with native residents of high altitude or to individuals living at sea level. Interestingly, HIF-2α and PHD2 polymorphisms are present at high frequencies in human populations living in the Tibetan or Andean plateaus and are associated with lower values of hemoglobin than in individuals living in other altitudes. This implies a selective advantage in these individuals in comparison with normal individuals developing polycythemia in high altitudes.
Increased but defective production of erythroblasts in the bone marrow, a process known as ineffective erythropoiesis, is a hallmark of \(\beta\)-thalassemia and other dyserythropoietic anemias.\(^{39}\) \(\beta\)-thalassemic patients and mouse models present inappropriately low expression of hepcidin relative to hepatic iron stores and high iron absorption rates.\(^{50}\) The molecular mechanism(s) by which the erythropoietic drive promotes hepcidin suppression during normal and stress erythropoiesis has not been fully elucidated so far. Possible regulators of hepcidin expression that have been proposed include changes in transferrin saturation, increased release of soluble molecules like growth differentiation factor 15 and twisted gastrulation homolog 1 from erythroblasts, and a direct effect of EPO on hepatocytes.\(^{51}\) Whether growth differentiation factor 15 or twisted gastrulation homolog 1 are upregulated in the gut in these conditions and whether they directly regulate iron absorption has not been examined.

Transfusion and pharmacologic chelation are the current treatments for patients with iron-loading anemias. However, both increased iron absorption and repetitive transfusions contribute to the massive organ iron load that leads to lethal complications. Anderson et al.\(^{58}\) recently showed that intestinal HIF-2 is essential for efficient erythropoiesis. It would be of interest to explore whether intestinal HIF-2 contributes to iron absorption and iron overload observed in \(\beta\)-thalassemic patients.

**Hereditary hemochromatosis**

HH is an autosomal recessive genetic disorder characterized by iron overload in the liver and other parenchyma. HH is caused by mutations in genes encoding signaling molecules that regulate hepcidin expression in response to iron, namely, HFE, TIR2, and HFE2, or mutations in the hepcidin gene (HAMP) itself. The age of onset and clinical phenotype varies depending on the particular gene that is mutated.\(^{92}\) Another hereditary iron overload disorder (termed FPN disease) is caused by autosomal dominant mutations in the FPN gene that impair hepcidin binding or alter FPN localization.\(^{93}\)

In regard to HFE-associated HH, different mutations have been identified; however, their penetrance is variable, and HFE homozygotes show phenotypic heterogeneity that ranges from complete absence of disease to severe iron overload in liver and pancreas leading to complications such as hepatic steatosis, hepato-cellular carcinoma, and diabetes. As previously mentioned, the HIF-2 transcription factor is crucial for the regulation of iron homeostasis by regulating the expression of DMT1 and DCYTB in the duodenum.\(^{52}\) Moreover, HIF-2\(a\) stabilization in the intestinal epithelium is sufficient to augment expression levels of DMT1, DCYTB, and FPN and leads to hepatic iron overload.\(^{29,53}\) As previously mentioned, high expression levels of duodenal Dmt1, Dcytb, and Fpn mRNA correlate with high iron absorption rates in various models characterized by low hepcidin expression. Importantly, deletion of intestinal Hif-2\(a\) in hepcidin knockout mice alleviates iron overload in the liver and pancreas by decreasing the expression of the duodenal DMT1, DCYTB, and FPN.\(^{54}\) These findings highlight the importance of HIF-2 in the transcriptional upregulation of genes involved in iron absorption in the context of hepcidin deficiency and suggest that HIF-2 could contribute to chronic iron accumulation in humans with HH. Recently, we showed that hepatic HIF-2\(a\) is dispensable for the homeostatic response to iron deficiency, but genetic stabilization of HIF-2\(a\) due to hepatic loss of VHL mediates a radical decrease in hepcidin expression that occurs in response to increased erythropoietic activity.\(^{54}\) Moreover, hepatic HIF-2\(a\) stabilization in the context of VHL deficiency leads to the development of hepatic steatosis and highly angiogenic tumors in mice.\(^{94}\) It has been previously proposed that DMT1\(^{95}\) and DCYTB\(^{96}\) 2 HIF-2 target genes, could act as genetic modifiers in HFE hemochromatosis. Therefore, whether polymorphic variation in HIF-2\(a\) itself contributes to the phenotypic heterogeneity of HFE-related hemochromatosis patients developing severe clinical features (steatosis and cancer) vs milder phenotypes would be of interest.

**Potential of the use of HIF-2 modulators in the treatment of iron-related diseases**

Although the role of HIF-2 in the pathogenesis of HFE or other forms of hemochromatosis in humans remains to be established, the previously discussed findings provide proof of concept that HIF-2 inhibitors could be employed therapeutically in patients with HH in combination with conventional phlebotomy. Increased iron absorption is also believed to contribute to iron loading in thalassemias and sideroblastic anemia, in addition to that caused by successive blood transfusions.\(^{90}\) Therefore, HIF-2 inhibitors might also prove beneficial for these patients by inhibiting both inefficient erythropoiesis and iron absorption. Currently, 1 study has identified a class of chemical compounds that inhibit HIF-2\(a\) translation by an IRP-dependent mechanism,\(^{97}\) but the pharmacokinetic properties and inhibitory potential of these compounds in vivo have not yet been determined. The recent demonstration of the critical role of the IRP-HIF-2 axis in intestinal iron absorption\(^{69,70}\) may encourage the evaluation of these HIF-2 inhibitors in vivo.

Finally, prolyl-hydroxylase inhibitors (PHIs) represent a promising potential alternative treatment for anemia.\(^{98,99}\) PHIs might be particularly advantageous in patients with anemia of renal failure, who are currently treated with intravenous/subcutaneous injections of recombinant EPO or related erythropoiesis-stimulating agents. PHIs improved hematologic parameters in a mouse model of chronic renal insufficiency by inducing hepatic Epo expression.\(^{100}\) However, the safety profile of PHIs and their ultimate efficacy in inducing the stabilization of both HIF-1 and HIF-2 in patients remain to be determined. Given the dual roles of HIF-2 in the regulation of iron absorption and EPO expression, PHIs or other compounds that specifically stabilize HIF-2 may represent possible therapeutic strategies for patients with iron-deficiency anemia or ACD.

**Acknowledgments**

The authors thank Sophie Vaulont (Institut Cochin) and Karin Finberg (Duke University) for critical reading of the manuscript.

**Authorship**

Contribution: M.M., P.M., and C.P. contributed to the writing of the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for M.M. is Centre for Stem Cells & Regenerative Medicine, Division of Genetics & Molecular Medicine, King’s College London School of Medicine, London, United Kingdom.

The current affiliation for P.M. is Department of Pharmacology and Cancer Biology, Duke University, Duke University Medical Center, Durham, NC.

Correspondence: Carole Peyssonnaux, INSERM, U1016, Institut Cochin, Faculté de Médecine Cochin Port Royal, 24, rue du Faubourg Saint Jacques, Paris, 75014, France; e-mail: carole.peyssonnaux@inserm.fr.
References


